The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-13 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Standard structure == The amino acids in a standard π-helix are arranged in a right-handed helical structure. Each amino acid corresponds to an 87° turn in the helix (i.e., the helix has 4.1 residues per turn), and a translation of 1.15 Å (0.115 nm) along the helical axis. Most importantly, the N-H group of an amino acid forms a hydrogen bond with the C=O group of the amino acid five residues earlier; this repeated i + 5 → i hydrogen bonding defines a π-helix. Similar structures include the 310 helix (i + 3 → i hydrogen bonding) and the α-helix (i + 4 → i hydrogen bonding).
==== Others ==== Other less important museums reflect the history of Le Havre and its maritime vocation. The apartment-control (Apartement-Temoine) was a standard apartment designed by in 1947–1950 and shows a place of daily life in the 1950s. The maritime museum displays objects related to the sea and the port. Finally, there are numerous exhibitions in the city such as the SPOT, a centre for contemporary art, art galleries, and Le Portique – a contemporary art space opened in 2008; the municipal library of Le Havre regularly organizes exhibitions.
=== Epigenetics === p53 function is also influenced by chromatin environment. The corepressor TRIM24 restricts p53 binding to epigenetically repressed loci by recognizing methylated histones. This interaction enables p53 to interpret local chromatin context and regulate gene expression in a locus-specific manner.
To compensate for this deficit in function, the colon increases its potassium secretion as part of an adaptive response. However, serum potassium remains elevated as the colonic compensating mechanism reaches its limits.
Sources: en.wikipedia.org
== Development == The penis derives from the genital tubercle, which develops into the phallus under the influence of androgens from the testis. Elongation draws the urethral folds forward to form the lateral walls of the urethral groove, whose epithelial lining becomes the urethral plate. The penile urethra is formed when the urethral folds enclose this plate, a process usually complete towards the end of the third month; the most distal part of the urethra forms at the end of the fourth month. Fusion of the two urethral folds gives rise to the spongy body, and two cavernous bodies arise above it to become the corpora cavernosa.
These cleaning methods may include soaking powdered biomineral samples in bleach prior to extracting amino acids, destroying the amino acids in the more porous, open areas while leaving the fraction trapped inside the grains unscathed.
mab: whole monoclonal antibody Fab: fragment, antigen-binding (one arm) F(ab')2: fragment, antigen-binding, including hinge region (both arms) Fab': fragment, antigen-binding, including hinge region (one arm) Variable fragments: scFv: single-chain variable fragment di-scFv: dimeric single-chain variable fragment sdAb: single-domain antibody BsAb: bispecific monoclonal antibody: 3funct: trifunctional antibody BiTE: bi-specific T-cell engager This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
During his tenure with the X-Men, Wolverine becomes a mentor for Kitty Pryde and later on Jubilee. Logan again encounters Jean, who has been resurrected and re-joins the X-Men, leading to resumption of Logan's rivalry with Cyclops. He is able to recall some of the trauma he received from the Weapon X program and tries to investigate his past, although his memories remain unreliable because of brainwashing and false memory implants. He meets Maverick, another former participant in the Weapon X project, and discovers that he had previously worked together with Sabretooth in Team X. During a conflict, the supervillain Magneto forcibly removes the adamantium from Wolverine's skeleton. This massive trauma causes his healing factor to burn out and leads to the discovery that his claws are actually bone. Wolverine leaves the X-Men for a time, embarking on a series of adventures during which his healing factor returns. After his return to the X-Men, Cable's son Genesis kidnaps Wolverine and attempts to re-bond adamantium to his skeleton. This is unsuccessful and causes Wolverine's mutation to accelerate out of control. He degenerates physically and mentally into a more primitive, bestial state. Elektra helps him to recover his humanity. Eventually, the villain Apocalypse captures Wolverine, brainwashes him into becoming the Horseman of Death, and successfully re-bonds adamantium to his skeleton. Wolverine overcomes Apocalypse's programming and returns to the X-Men.
George Rennie (1801 or 1802 in Phantassie, East Lothian – 1860 in London), sculptor, politician and governor Mary Ellaline Terriss, Lady Hicks (1871 in Stanley – 1971 (aged 100) in Hampstead, London), known professionally as Ellaline Terriss, a popular English actress and singer, best known for her performances in Edwardian musical comedies Edward Binnie (1884 in Stanley – 1956 in Sandefjord, Norway), the second resident magistrate of South Georgia, serving from October 1914 to April 1927, when he resided at King Edward Point; previously served as customs officer on East Falkland Island McDonald Hobley (1917 in Stanley – 1987), one of the first BBC Television continuity announcers from 1946 to 1956 Sir Rex Hunt CMG (1926 in Redcar – 2012 in Stockton on Tees), Governor during the Falklands War Gerald Reive (born 1937 in the Falkland Islands), a New Zealand-based athlete, a lawn bowler at the 2010 Commonwealth Games Terry Peck MBE, CPM (1938 – 2006 both in Stanley), soldier, policeman and legislator Edward Neill "Ted" Baker CNZM (born 1942 in Stanley), a New Zealand scientist specialising in protein purification and crystallization and bioinformatics Alejandro Betts (1947 – 2020), a Falklands-born Argentine air-traffic controller, notable for being the only Falkland Islander to support Argentina's claim to the Falkland Islands Mensun Bound (born 1953 in Port Stanley) is a British marine archaeologist, based in Oxford, Triton Senior Research Fellow in Marine Archaeology at Oxford University James Peck (born 1968 in Stanley), an artist and writer who at one time held both Argentine and British citizenship but has since renounced his Argentine citizenship.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.